• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Kazmaier Jessica

    7/28/23 4:09:26 PM ET
    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $RAD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Kazmaier Jessica

    (Last) (First) (Middle)
    C/O RITE AID CORPORATION
    1200 INTREPID AVENUE, 2ND FLOOR

    (Street)
    PHILADELPHIA PA 19112

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RITE AID CORP [ RAD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, Chief HR Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    07/27/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/27/2023 F 6,934(1) D $1.58 89,794 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares are being surrendered to satisfy tax withholding obligation with respect to shares on which restrictions are lapsing.
    Remarks:
    /s/ Francine Henderson, attorney-in-fact 07/28/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAD

    DatePrice TargetRatingAnalyst
    4/7/2022$16.00 → $1.00Hold → Sell
    Deutsche Bank
    6/25/2021$21.00 → $12.00Neutral → Underweight
    JP Morgan
    More analyst ratings

    $RAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Carenet Health Acquiring Health Dialog, Enhancing Clinical Team and Advancing Insights-Driven Platform Dedicated to the Business of Healthcare

      Expanded personalized population health capabilities support better health journeys for patients Carenet Health, a trusted partner in helping organizations simplify and power the business of healthcare, is excited to announce it is acquiring Health Dialog, a worldwide leader in delivering clinical decision support offerings. This acquisition enables Carenet to leverage its combined platform, analytics and clinicians to deliver greater efficiency and outcomes-based financial performance for clients. Health Dialog provides personalized population health services to health plans, providers, employers and pharmaceutical manufacturers. Carenet is acquiring all assets of Health Dialog from

      3/6/24 11:05:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Receives Court Approval of "First Day" Motions to Support Business Operations

      Secures Interim Approval to Access Up to $3.45 Billion in Debtor-in-Possession Financing Continues to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (OTC:RADCQ) ("Rite Aid" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on October 15, 2023. The Court granted interim approval to access up to $3.45 billion in debtor-in-possession financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the Company th

      10/17/23 11:05:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

      Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Financials

    Live finance-specific insights

    See more
    • Rite Aid Corporation Reports Fiscal 2024 First Quarter Results

      Revenues of $5.7 Billion, Compared to Prior Year Revenues of $6.0 Billion Retail Comparable Same Store Prescriptions Increased 4.7 Percent – Comparable Same Store Prescriptions, Excluding COVID Impact, Increased 7.4 Percent Net Loss of $306.7 Million Compared to Prior Year Net Loss of $110.2 Million – Increase Largely Attributable to a Goodwill Impairment Charge at Elixir Adjusted EBITDA of $91.7 Million, Compared to Prior Year Adjusted EBITDA of $100.1 Million Updates Fiscal 2024 Outlook Rite Aid Corporation (NYSE:RAD) today reported operating results for its first fiscal quarter ended June 3, 2023. "Our first quarter results were driven by strong script growth, solid ph

      6/29/23 7:00:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid to Release First Quarter Results on June 29

      Rite Aid Corporation (NYSE:RAD) will release financial results for its Fiscal 2024 First Quarter, which ended June 3, 2023, on Thursday, June 29, 2023. The company will hold an analyst call at 8:30 a.m. ET with remarks by Rite Aid's management team. The call will be broadcast at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. ET on Thursday, June 29, 2023, through 11:59 p.m. ET on July 29, 2023. To access the replay of the call, please dial (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. ET Thursda

      6/12/23 8:30:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation Reports Fiscal 2023 Fourth Quarter and Full Year Results and Provides Fiscal 2024 Outlook

      Fourth Quarter Highlights: Revenues of $6.1 billion, Comparable to Prior Year Retail Comparable Same Store Prescriptions Increased 5.2 Percent – Comparable Same Store Prescriptions, Excluding COVID Impacts, Increased 9.7 Percent Net Loss per Share of $4.39, Compared to Prior Year Net Loss per Share of $7.18 Adjusted EBITDA of $128.6 million, Compared to the Prior Year Adjusted EBITDA of $106.1 million Completed Tender Offer for $165 million of our 2025 notes – Reducing Amount Outstanding to $320 million From $600 million at Beginning of Fiscal 2022 Full Year Highlights: Revenues of $24.1 billion, Compared to Prior Year Revenues of $24.6 billion Retail Comparable Same

      4/20/23 7:00:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      2/9/23 11:32:52 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      7/11/22 1:13:14 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      3/9/22 8:44:09 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rite Aid downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Rite Aid from Hold to Sell and set a new price target of $1.00 from $16.00 previously

      4/7/22 7:32:45 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid downgraded by JP Morgan with a new price target

      JP Morgan downgraded Rite Aid from Neutral to Underweight and set a new price target of $12.00 from $21.00 previously

      6/25/21 7:27:02 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Deutsche Bank reiterated coverage on Rite Aid with a new price target

      Deutsche Bank reiterated coverage of Rite Aid with a rating of Hold and set a new price target of $27.00 from $17.00 previously

      3/25/21 9:26:08 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Rite Aid Corporation

      NT 10-Q - RITE AID CORP (0000084129) (Filer)

      1/12/24 5:00:11 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - RITE AID CORP (0000084129) (Filer)

      12/27/23 6:03:09 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - RITE AID CORP (0000084129) (Filer)

      11/1/23 4:30:23 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Dupaul Christopher W. claimed ownership of 34,525 shares

      3 - RITE AID CORP (0000084129) (Issuer)

      8/24/23 4:33:34 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Schroeder Matt

      4 - RITE AID CORP (0000084129) (Issuer)

      7/28/23 4:10:16 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Mennen Justin L.

      4 - RITE AID CORP (0000084129) (Issuer)

      7/28/23 4:09:48 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

      Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Takes Steps to Accelerate Transformation and Position Company for Long-Term Success

      Reaches Agreement in Principle with Key Creditors on the Terms of Financial Restructuring Plan Initiates Voluntary Chapter 11 Process to Implement a Consensual Financial Restructuring That Will Significantly Reduce Debt and Enable Execution of Key Initiatives Receives Commitment for $3.45 Billion in New Financing to Support Business Operations Continuing to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the Co

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples